SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Kim Seong Min)
 

Search: WFRF:(Kim Seong Min) > Cardiovascular even...

  • Jung, Se YongYonsei Univ, South Korea (author)

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2021-10-31
  • Wiley,2022
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-181065
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-181065URI
  • https://doi.org/10.1111/cts.13168DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|Yonsei University College of Medicine for 2021 [2021-32-0049] Funding Source: Medline
  • On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID-19), increasing remdesivir prescriptions worldwide. However, potential cardiovascular (CV) toxicities associated with remdesivir remain unknown. We aimed to characterize the CV adverse drug reactions (ADRs) associated with remdesivir using VigiBase, an individual case safety report database of the World Health Organization (WHO). Disproportionality analyses of CV-ADRs associated with remdesivir were performed using reported odds ratios and information components. We conducted in vitro experiments using cardiomyocytes derived from human pluripotent stem cell cardiomyocytes (hPSC-CMs) to confirm cardiotoxicity of remdesivir. To distinguish drug-induced CV-ADRs from COVID-19 effects, we restricted analyses to patients with COVID-19 and found that, after adjusting for multiple confounders, cardiac arrest (adjusted odds ratio [aOR]: 1.88, 95% confidence interval [CI]: 1.08-3.29), bradycardia (aOR: 2.09, 95% CI: 1.24-3.53), and hypotension (aOR: 1.67, 95% CI: 1.03-2.73) were associated with remdesivir. In vitro data demonstrated that remdesivir reduced the cell viability of hPSC-CMs in time- and dose-dependent manners. Physicians should be aware of potential CV consequences following remdesivir use and implement adequate CV monitoring to maintain a tolerable safety margin.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Kim, Min SeoKorea Univ, South Korea; Sungkyunkwan Univ, South Korea (author)
  • Li, HanUniv Florida, FL USA (author)
  • Lee, Keum HwaYonsei Univ, South Korea (author)
  • Koyanagi, AiUniv Barcelona, Spain; ICREA, Spain; Inst Salud Carlos III, Spain (author)
  • Solmi, MarcoUniv Ottawa, Canada; Ottawa Hosp, Canada; Univ Ottawa, Canada (author)
  • Kronbichler, AndreasMed Univ Innsbruck, Austria (author)
  • Dragioti, ElenaLinköpings universitet,Avdelningen för prevention, rehabilitering och nära vård,Medicinska fakulteten,Region Östergötland, Smärt och rehabiliteringscentrum(Swepub:liu)eledr71 (author)
  • Tizaoui, KalthoumTunis El Manar Univ, Tunisia (author)
  • Cargnin, SarahUniv Piemonte Orientale, Italy (author)
  • Terrazzino, SalvatoreUniv Piemonte Orientale, Italy (author)
  • Hong, Sung HwiYonsei Univ, South Korea (author)
  • Abou Ghayda, RamyUniv Hosp, OH USA; Case Western Reserve Univ, OH 44106 USA (author)
  • Kim, Nam KyunEmory Univ, GA 30322 USA; Yonsei Univ, South Korea (author)
  • Chung, Seo KyoungEwha Womans Univ, South Korea (author)
  • Jacob, LouisUniv Barcelona, Spain; Univ Versailles St Quentin En Yvelines, France (author)
  • Salem, Joe-ElieSorbonne Univ, France (author)
  • Yon, Dong KeonSeoul Natl Univ, South Korea (author)
  • Lee, Seung WonSejong Univ, South Korea (author)
  • Kostev, KarelUniv Clin Marburg, Germany (author)
  • Kim, Ah YoungYonsei Univ, South Korea (author)
  • Jung, Jo WonYonsei Univ, South Korea (author)
  • Choi, Jae YoungYonsei Univ, South Korea (author)
  • Shin, Jin SooKorea Res Inst Chem Technol, Germany (author)
  • Park, Soon-JungT&R Biofab Co Ltd, Germany (author)
  • Choi, Seong WooSeoul Natl Univ, South Korea (author)
  • Ban, KiwonCity Univ Hong Kong, Peoples R China (author)
  • Moon, Sung-HwanT&R Biofab Co Ltd, Germany (author)
  • Go, Yun YoungCity Univ Hong Kong, Peoples R China (author)
  • Shin, Jae IlYonsei Univ, South Korea (author)
  • Smith, LeeAnglia Ruskin Univ, England (author)
  • Yonsei Univ, South KoreaKorea Univ, South Korea; Sungkyunkwan Univ, South Korea (creator_code:org_t)

Related titles

  • In:Clinical and Translational Science: Wiley15:2, s. 501-5131752-80541752-8062

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view